Sengupta S, Deodhar L, Kapoor H, Badrinath S, Menon S S
Calcutta Medical Research Institute.
J Indian Med Assoc. 2000 Apr;98(4):196-7.
In a multicentric study at several leading hospitals of this country, microbiological assessment was carried out in 500 specimens from patients suffering from respiratory tract infections (RTIs; both upper and lower) for a period of 6 months from January, 1999 to June, 1999. The antibiotic sensitivity study was done in 201 isolates from 500 different specimens of throat swab, postpharyngeal swab, sinusitis drainage fluid, sputum, broncho-alveolar lavage (BL), etc. Ceftibuten, an orally active third generation cephalosporin showed encouraging results when compared with seven other selected antibiotics used for RTI. The majority of the patients with acute or chronic RTIs showed an excellent in vitro response to ceftibuten in the analysis of the isolates. Seventy to ninety per cent of the isolated respiratory pathogens were found to be sensitive to ceftibuten in vitro; which offers a promising alternative to other antibiotics included in this study.
在该国几家顶尖医院进行的一项多中心研究中，于1999年1月至1999年6月的6个月期间，对500例患有呼吸道感染（包括上呼吸道和下呼吸道感染）患者的标本进行了微生物学评估。对来自500份不同标本（咽拭子、咽后壁拭子、鼻窦炎引流液、痰液、支气管肺泡灌洗等）的201株菌株进行了抗生素敏感性研究。与用于呼吸道感染的其他七种选定抗生素相比，口服活性第三代头孢菌素头孢布烯显示出令人鼓舞的结果。在对分离株的分析中，大多数急性或慢性呼吸道感染患者对头孢布烯表现出良好的体外反应。在体外发现70%至90%的分离呼吸道病原体对头孢布烯敏感；这为该研究中包含的其他抗生素提供了一个有前景的替代选择。
